Maximizing the Survival of Amyotrophic Lateral Sclerosis Patients: Current Perspectives

Abstract EN

Amyotrophic lateral sclerosis is a neurodegenerative disease that leads to loss of the upper and lower motor neurons.

Almost 90% of all cases occur in the sporadic form, with the rest occurring in the familial form.

The disease has a poor prognosis, with only two disease-modifying drugs approved by the United States Food and Drug Administration (FDA).

The approved drugs for the disease have very limited survival benefits.

Edaravone is a new FDA-approved medication that may slow the disease progression by 33% in a selected subgroup of ALS patients.

This paper covers the various interventions that may provide survival benefits, such as early diagnosis, medications, gene therapy, stem cell therapy, diet, nutritional supplements, multidisciplinary clinics, and mechanical invasive and noninvasive ventilation.

The recent data on masitinib, the role of enteral feeding, gene therapy, and stem cell therapy is discussed.